Etilevodopa
Chemical compound
- N04BA06 (WHO) (combination with decarboxylase inhibitor)
- ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
- 37178-37-3 Y
- 170345
- 148944 Y
- 895X917GYE
- D04097 Y
- DTXSID10905092
- Interactive image
- O=C(OCC)[C@@H](N)Cc1cc(O)c(O)cc1
InChI
- InChI=1S/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1 Y
- Key:NULMGOSOSZBEQL-QMMMGPOBSA-N Y
Etilevodopa (TV-1203) is a dopaminergic agent which was developed as a treatment for Parkinson's disease.[1] It is the ethyl ester of levodopa. It was never marketed.
See also
- Melevodopa
References
- ^ Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E (November–December 2003). "Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study". Clinical Neuropharmacology. 26 (6): 322–6. doi:10.1097/00002826-200311000-00012. PMID 14646613. S2CID 23992241.
- v
- t
- e
DA precursors | |
---|---|
DA receptor agonists |
|
MAO-B inhibitors | |
COMT inhibitors | |
AAAD inhibitors |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e